NF-κB in the crosshairs: Rethinking an old riddle

Jason Bennett, Daria Capece, Federica Begalli, Daniela Verzella, Daniel D'Andrea, Laura Tornatore, Guido Franzoso

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)
134 Downloads (Pure)


Constitutive NF-κB signalling has been implicated in the pathogenesis of most human malignancies and virtually all non-malignant pathologies. Accordingly, the NF-κB pathway has been aggressively pursued as an attractive therapeutic target for drug discovery. However, the severe on-target toxicities associated with systemic NF-κB inhibition have thus far precluded the development of a clinically useful, NF-κB-targeting medicine as a way to treat patients with either oncological or non-oncological diseases. This minireview discusses some of the more promising approaches currently being developed to circumvent the preclusive safety liabilities of global NF-κB blockade by selectively targeting pathogenic NF-κB signalling in cancer, while preserving the multiple physiological functions of NF-κB in host defence responses and tissue homeostasis.
Original languageEnglish
Pages (from-to)108-112
Number of pages5
JournalInternational Journal of Biochemistry and Cell Biology
Early online date23 Dec 2017
Publication statusPublished - Feb 2018
Externally publishedYes

Bibliographical note

© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (


  • Cancer
  • NF-κB
  • BIKKβ
  • GADD45β
  • DTP3


Dive into the research topics of 'NF-κB in the crosshairs: Rethinking an old riddle'. Together they form a unique fingerprint.

Cite this